Bisphosphonate therapy in chronic diffuse sclerosing osteomyelitis/tendoperiostitis of the mandible: Retrospective case series

J Craniomaxillofac Surg. 2022 Jul;50(7):599-604. doi: 10.1016/j.jcms.2022.05.011. Epub 2022 Jun 11.

Abstract

This study aims to evaluate short-term and long-term results of bisphosphonate therapy in patients with diffuse sclerosing osteomyelitis/tendoperiostitis (DSO/TP) of the mandible. Eighteen patients (12 female, 6 male) aged 34.8 ± 22.2 years with DSO/TP of the mandible that were treated with bisphosphonates were included. In 16 patients, the bisphosphonate treatment led to remission with decrease of symptoms (pain, swelling of the cheek, trismus, tenderness of masticatory muscles) with a follow-up period of 4.5 (0.8-11.9) years between start of bisphosphonate treatment and latest follow-up consult. Of these, three patients were still in need of regular bisphosphonate therapy. Two patients were lost to follow-up. Bisphosphonate therapy is a treatment option for DSO/TP of the mandible that is associated with a high chance of remission of symptoms. Within the limitations of the study it seems that this treatment might be an effective second step in DSO/TP refractory to conservative treatment.

Keywords: Bisphosphonate therapy; Chronic tendoperiostitis; Diffuse sclerosing osteomyelitis; Pain.

Publication types

  • Case Reports

MeSH terms

  • Diphosphonates / therapeutic use
  • Female
  • Humans
  • Male
  • Mandible
  • Mandibular Diseases* / complications
  • Osteomyelitis* / complications
  • Periostitis* / complications
  • Retrospective Studies

Substances

  • Diphosphonates